Clinically relevant amplification drivers such as ERBB2 in breast cancers (FF: 7.7%, FFPE:4.7%), GNAS (20q13) in colorectal cancers (FF: 6.4%, FFPE: 4.5%), and CCND1 (FF: 6.9%, FFPE: 8.5%) were comparably retrieved. Here, CCND1 is linked to breast carcinoma.